Clicky

Adial Pharmaceuticals, Inc(ADIL)

Description: Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of a therapeutic agent for the treatment of alcohol use disorder (AUD). Its lead drug product is AD04. AD04 is a selective serotonin-3 antagonist. AD04 can also be used for the treatment of other addictive disorders, such as obesity, smoking, and drug addiction. The Company has completed a Phase-II clinical trials of AD04.


Keywords: Biopharmaceutical Medication Alcohol Mental Health Smoking Obesity Psychiatry Drug Products Addiction Addictive Disorders Alcoholism

Home Page: www.adialpharma.com

ADIL Technical Analysis

1180 Seminole Trail
Charlottesville, VA 22901
United States
Phone: 434 422 9800


Officers

Name Title
Mr. Cary John Claiborne MBA CEO, Pres & Director
Mr. Joseph A. M. Truluck M.B.A., MBA CFO, Treasurer & Sec.
Dr. Bankole A. Johnson DSc, FRCPsych, M.D., M.Phil, Ph.D. Founder & Chief Medical Officer
Mr. John R. Martin J.D. Gen. Counsel
Mr. Alex Lugovoy Chief Bus. Officer
Dr. Jack W. Reich Ph.D. Head of Regulatory
Mr. Mark H. Peikin Chief Strategy Officer & Chief Devel. Officer
Mr. Lawrence Goldman CPA Controller
Ms. Catherine Fratila Controller

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.1791
Price-to-Sales TTM: 0
IPO Date: 2018-07-30
Fiscal Year End: December
Full Time Employees: 16
Back to stocks